<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01196819</url>
  </required_header>
  <id_info>
    <org_study_id>Target I</org_study_id>
    <nct_id>NCT01196819</nct_id>
  </id_info>
  <brief_title>Randomized MicroPort's Firehawk DES Versus Xience V: TARGET I Trial</brief_title>
  <official_title>A Prospective Multi-center Randomized Trial Assessing the Safety and Effectiveness of Biodegradable Polymer Target Release Rapamycin-Eluting STent vs. XIENCE V Everolimus-Eluting Stent for the Treatment of Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai MicroPort Medical (Group) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai MicroPort Medical (Group) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate new generation drug eluting stent (DES) of MicroPort
      of its safety, efficacy and delivery system in treating CAD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint is in-stent late lumen loss after 9 months of the stent implantation.
      The secondary endpoint is in-stent percent diameter stenosis.This study is based on
      non-inferior assumption (vs. Xience V), requiring both endpoints reach statistical
      significance. Prespecified OCT follow-up is planned at 3-Year after index procedure at 3
      chosen hospitals.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2010</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>9 Months In-stent Late Lumen Loss</measure>
    <time_frame>9 months</time_frame>
    <description>To observe in-stent late lumen loss after 9 months of stent implantation It means the difference between the minimal lumen diameter immediately after stent implantation and the minimal lumen diameter by angiography review 9 months after the procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>9 Months In-stent Diameter Stenosis</measure>
    <time_frame>9 months</time_frame>
    <description>the in-stent diameter stenosis 9 months post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Failure(TLF) Rate</measure>
    <time_frame>1 years after index PCI</time_frame>
    <description>Percentage of participants with the determination of TLF. TLF is the composite of sudden cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLF(Target Lumen Failure) Rate</measure>
    <time_frame>3 years after index PCI (Percutaneous Coronary Intervention)</time_frame>
    <description>percentage of participants with the determination of TLF, TLF include target vessel myocardial infarction, symptom-driven target lesion revascularization and sudden cardiac death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLF(Target Lumen Failure)</measure>
    <time_frame>5 years after index PCI</time_frame>
    <description>percentage of participants with the determination of TLF, TLF include target vessel myocardial infarction, symptom-driven target lesion revascularization and sudden cardiac death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stent Thrombsis (ARC Defined Definite/Probable)</measure>
    <time_frame>1 years after index PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stent Thrombsis (ARC Defined Definite/Probable)</measure>
    <time_frame>3 years after index PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stent Thrombsis (ARC Defined Definite/Probable)</measure>
    <time_frame>5 years after index PCI</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">458</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Xience V</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Implantation of Xience V drug eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Firehawk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of Firehawk drug eluting stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Firehawk</intervention_name>
    <description>Implantation of Firehawk drug eluting stent</description>
    <arm_group_label>Firehawk</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xience V</intervention_name>
    <description>Implantation of Xience V drug eluting stent</description>
    <arm_group_label>Xience V</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-75, male or women who are not pregnant

          -  Evidence of non-symptomatic ischemia, stable or non-stable angina or past heart attack
             cases

          -  Target lesion is primary, single artery and single lesion of coronary artery

          -  Target lesion vessel length ≤24mm, diameter 2.25mm－4.0mm

          -  Lesion diameter stenosis ≥70%

          -  Candidates understand the study, willing to sign Consent of Agreement and to willing
             to accept follow-up For long lesion group, at least one target lesion length
             ≥28mm，diameter 2.5mm－4.0mm, and one lesion needs to implant 33mm 0r 38mm long stent

        Exclusion Criteria:

          -  Acute heart attack within one week

          -  Chronic complete stenosis (TIMI 0), left main lesion, three branches need to treat,
             branch vessel diameter ≤2.5mm and bypass lesion

          -  Calcified lesion failed in pre-dilation and twisted lesion

          -  In-stent restenosis

          -  Stent implanted within one year

          -  Severe heart failure (NYHA above III) or left ventricle EF &lt;40%

          -  Renal function damage, blood creatinine &gt;2.0mg/dl

          -  Bleeding risk; allergic to drugs and agents used in procedure/treatment

          -  Life expectation &lt; 12 months

          -  No compliances to the protocol

          -  Heart implantation cases

        Pre-specified OCT inclusion/exclusion criteria:

          -  Patients underwent 9-month angio F/U

          -  No binary restenosis at 9-month

          -  LLL between -0.01~0.2mm

          -  No mix-implanted stent

          -  No more than one bail-out stent

          -  No TLR occurred at 3 years after PCI

          -  The target vessel able to deliver the OCT catheter
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Runlin Gao, Pro &amp; MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuwai Hospital, Beijing, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>September 6, 2010</study_first_submitted>
  <study_first_submitted_qc>September 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2010</study_first_posted>
  <results_first_submitted>February 18, 2016</results_first_submitted>
  <results_first_submitted_qc>July 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 22, 2018</results_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Xience V DES as Comparative Arm</title>
          <description>Use Xience V DES as control group
DES implantation: Implant DES for CAD cases</description>
        </group>
        <group group_id="P2">
          <title>MicroPort Firehawk DES</title>
          <description>Use MicroPort's new generation of Firehawk drug eluting stent
DES implantation: Implant DES for CAD cases</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="231"/>
                <participants group_id="P2" count="227"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="225"/>
                <participants group_id="P2" count="227"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Xience V DES as Comparative Arm</title>
          <description>Use Xience V DES as control group
DES implantation: Implant DES for CAD cases</description>
        </group>
        <group group_id="B2">
          <title>MicroPort Firehawk DES</title>
          <description>Use MicroPort's new generation of Firehawk drug eluting stent
DES implantation: Implant DES for CAD cases</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="231"/>
            <count group_id="B2" value="227"/>
            <count group_id="B3" value="458"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.97" spread="9.39"/>
                    <measurement group_id="B2" value="58.95" spread="9.42"/>
                    <measurement group_id="B3" value="59" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="231"/>
                    <measurement group_id="B2" value="227"/>
                    <measurement group_id="B3" value="458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>9 Months In-stent Late Lumen Loss</title>
        <description>To observe in-stent late lumen loss after 9 months of stent implantation It means the difference between the minimal lumen diameter immediately after stent implantation and the minimal lumen diameter by angiography review 9 months after the procedure</description>
        <time_frame>9 months</time_frame>
        <population>Angiographic follow-up at nine months was completed in 87.6% (199/227) of the Firehawk DES group and 87.4% (202/231) of the Xience V DES group.</population>
        <group_list>
          <group group_id="O1">
            <title>Xience V DES as Comparative Arm</title>
            <description>Use Xience V DES as control group
DES implantation: Implant DES for CAD cases</description>
          </group>
          <group group_id="O2">
            <title>MicroPort Firehawk DES</title>
            <description>Use MicroPort's new generation of Firehawk drug eluting stent
DES implantation: Implant DES for CAD cases</description>
          </group>
        </group_list>
        <measure>
          <title>9 Months In-stent Late Lumen Loss</title>
          <description>To observe in-stent late lumen loss after 9 months of stent implantation It means the difference between the minimal lumen diameter immediately after stent implantation and the minimal lumen diameter by angiography review 9 months after the procedure</description>
          <population>Angiographic follow-up at nine months was completed in 87.6% (199/227) of the Firehawk DES group and 87.4% (202/231) of the Xience V DES group.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.18"/>
                    <measurement group_id="O2" value="0.13" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: Pe - Pc≥ ∆, H1: Pe - Pc &lt; ∆. Pe and Pc are the mean 9-month in-stent late loss for the subject in the Firehawk DES group and the Xience group, respectively. ∆ is the non-inferiority margin. A two-sided upper 95% confidence bound will be calculated for the difference in 9-month in-stent late loss .</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin is 0.13mm, if the two-sided upper 95% confidence bound is &lt;Δ, the Firehawk Stent being tested will be considered non-inferior to the control. This corresponds to a P value &lt;0.05 from a two-sided Student t-test comparing the difference between FirehawkStent and Xience stent to delta.</non_inferiority_desc>
            <p_value>0.94</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>0.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>9 Months In-stent Diameter Stenosis</title>
        <description>the in-stent diameter stenosis 9 months post-procedure</description>
        <time_frame>9 months</time_frame>
        <population>Angiographic follow-up at nine months was completed in 87.6% (199/227) of the Firehawk DES group and 87.4% (202/231) of the Xience V DES group.</population>
        <group_list>
          <group group_id="O1">
            <title>Xience V DES as Comparative Arm</title>
            <description>Use Xience V DES as control group
DES implantation: Implant DES for CAD cases</description>
          </group>
          <group group_id="O2">
            <title>MicroPort Firehawk DES</title>
            <description>Use MicroPort's new generation of Firehawk drug eluting stent
DES implantation: Implant DES for CAD cases</description>
          </group>
        </group_list>
        <measure>
          <title>9 Months In-stent Diameter Stenosis</title>
          <description>the in-stent diameter stenosis 9 months post-procedure</description>
          <population>Angiographic follow-up at nine months was completed in 87.6% (199/227) of the Firehawk DES group and 87.4% (202/231) of the Xience V DES group.</population>
          <units>percentage of diameter stenosis</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.51" spread="7.37"/>
                    <measurement group_id="O2" value="11.85" spread="9.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Assume the in-stent percent diameter stenosis of both FIREHAWK and XIENCE V are 16 ± 16%, the non-inferiority value is 5%, the level of statistical significance is 0.05 (bilateral test), the power is 85%.</non_inferiority_desc>
            <p_value>0.69</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Failure(TLF) Rate</title>
        <description>Percentage of participants with the determination of TLF. TLF is the composite of sudden cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR).</description>
        <time_frame>1 years after index PCI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Xience V DES as Comparative Arm</title>
            <description>Use Xience V DES as control group
DES implantation: Implant DES for CAD cases</description>
          </group>
          <group group_id="O2">
            <title>MicroPort Firehawk DES</title>
            <description>Use MicroPort's new generation of Firehawk drug eluting stent
DES implantation: Implant DES for CAD cases</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Failure(TLF) Rate</title>
          <description>Percentage of participants with the determination of TLF. TLF is the composite of sudden cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR).</description>
          <units>percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TLF(Target Lumen Failure) Rate</title>
        <description>percentage of participants with the determination of TLF, TLF include target vessel myocardial infarction, symptom-driven target lesion revascularization and sudden cardiac death.</description>
        <time_frame>3 years after index PCI (Percutaneous Coronary Intervention)</time_frame>
        <population>3 patients in Xience V DES group and 5 patients in Firehawk DES group failed to be contacted.</population>
        <group_list>
          <group group_id="O1">
            <title>Xience V DES as Comparative Arm</title>
            <description>Use Xience V DES as control group
DES implantation: Implant DES for CAD cases</description>
          </group>
          <group group_id="O2">
            <title>MicroPort Firehawk DES</title>
            <description>Use MicroPort's new generation of Firehawk drug eluting stent
DES implantation: Implant DES for CAD cases</description>
          </group>
        </group_list>
        <measure>
          <title>TLF(Target Lumen Failure) Rate</title>
          <description>percentage of participants with the determination of TLF, TLF include target vessel myocardial infarction, symptom-driven target lesion revascularization and sudden cardiac death.</description>
          <population>3 patients in Xience V DES group and 5 patients in Firehawk DES group failed to be contacted.</population>
          <units>percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.51"/>
                    <measurement group_id="O2" value="4.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TLF(Target Lumen Failure)</title>
        <description>percentage of participants with the determination of TLF, TLF include target vessel myocardial infarction, symptom-driven target lesion revascularization and sudden cardiac death.</description>
        <time_frame>5 years after index PCI</time_frame>
        <population>6 patients in Xience V DES group and 10 patients in Firehawk DES group failed to be contacted.</population>
        <group_list>
          <group group_id="O1">
            <title>Xience V DES as Comparative Arm</title>
            <description>Use Xience V DES as control group
DES implantation: Implant DES for CAD cases</description>
          </group>
          <group group_id="O2">
            <title>MicroPort Firehawk DES</title>
            <description>Use MicroPort's new generation of Firehawk drug eluting stent
DES implantation: Implant DES for CAD cases</description>
          </group>
        </group_list>
        <measure>
          <title>TLF(Target Lumen Failure)</title>
          <description>percentage of participants with the determination of TLF, TLF include target vessel myocardial infarction, symptom-driven target lesion revascularization and sudden cardiac death.</description>
          <population>6 patients in Xience V DES group and 10 patients in Firehawk DES group failed to be contacted.</population>
          <units>percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67"/>
                    <measurement group_id="O2" value="5.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.77</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stent Thrombsis (ARC Defined Definite/Probable)</title>
        <time_frame>1 years after index PCI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Xience V DES as Comparative Arm</title>
            <description>Use Xience V DES as control group
DES implantation: Implant DES for CAD cases</description>
          </group>
          <group group_id="O2">
            <title>MicroPort Firehawk DES</title>
            <description>Use MicroPort's new generation of Firehawk drug eluting stent
DES implantation: Implant DES for CAD cases</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent Thrombsis (ARC Defined Definite/Probable)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stent Thrombsis (ARC Defined Definite/Probable)</title>
        <time_frame>3 years after index PCI</time_frame>
        <population>3 patients in Xience V DES group and 5 patients in Firehawk DES group failed to be contacted.</population>
        <group_list>
          <group group_id="O1">
            <title>Xience V DES as Comparative Arm</title>
            <description>Use Xience V DES as control group
DES implantation: Implant DES for CAD cases</description>
          </group>
          <group group_id="O2">
            <title>MicroPort Firehawk DES</title>
            <description>Use MicroPort's new generation of Firehawk drug eluting stent
DES implantation: Implant DES for CAD cases</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent Thrombsis (ARC Defined Definite/Probable)</title>
          <population>3 patients in Xience V DES group and 5 patients in Firehawk DES group failed to be contacted.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stent Thrombsis (ARC Defined Definite/Probable)</title>
        <time_frame>5 years after index PCI</time_frame>
        <population>6 patients in Xience V DES group and 10 patients in Firehawk DES group failed to be contacted.</population>
        <group_list>
          <group group_id="O1">
            <title>Xience V DES as Comparative Arm</title>
            <description>Use Xience V DES as control group
DES implantation: Implant DES for CAD cases</description>
          </group>
          <group group_id="O2">
            <title>MicroPort Firehawk DES</title>
            <description>Use MicroPort's new generation of Firehawk drug eluting stent
DES implantation: Implant DES for CAD cases</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent Thrombsis (ARC Defined Definite/Probable)</title>
          <population>6 patients in Xience V DES group and 10 patients in Firehawk DES group failed to be contacted.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Xience V DES as Comparative Arm</title>
          <description>Use Xience V DES as control group
DES implantation: Implant DES for CAD cases</description>
        </group>
        <group group_id="E2">
          <title>MicroPort Firehawk DES</title>
          <description>Use MicroPort's new generation of Firehawk drug eluting stent
DES implantation: Implant DES for CAD cases</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Definite/probable in-stent thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>coronary revascularization</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kefei Li</name_or_title>
      <organization>Shanghai Microport Medical (Group) Co.,Ltd.</organization>
      <phone>+86-21-38954600×6700</phone>
      <email>kfli@microport.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

